Health · Medical Research · 2 hrs ago
GLP-1 drugs did not significantly change injection frequency for diabetic eye disease
A large study found GLP-1 drugs did not significantly change injection frequency for people with diabetic macular edema.
The study was presented in New Orleans and looked at anti-VEGF injections, a treatment used for the condition.
It was a retrospective cohort study, meaning researchers examined existing patient information.
The researchers tracked treatment over 24 months of follow-up.
The finding suggests GLP-1 drugs did not lead to a sustained change in how often patients received injections.
The study does not establish what happens beyond those 24 months.
GLP-1 receptor agonists did not significantly affect anti-VEGF treatment frequency in patients with diabetic macular edema, a study found.
The finding came from a large retrospective cohort study.
Patients were followed for 24 months.
- Who
- Patients with diabetic macular edema.
- What
- GLP-1 receptor agonists did not significantly affect anti-VEGF treatment frequency.
- When
- Over 24 months of follow-up.
- Where
- New Orleans, where the study was reported.
- Why
- Not stated
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Study type
- Large retrospective cohort study
- Follow-up
- 24 months
- Condition
- Diabetic macular edema (DME)
- Treatment frequency
- GLP-1 receptor agonists did not significantly affect anti-VEGF treatment frequency











